X

Trial Profile

Phase I/II Study of Stereotactic Radiation and Abemaciclib in the Management of Hormone Receptor Positive HER2 Negative Breast Cancer Brain Metastases

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 19 Jul 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Abemaciclib (Primary) ; Aromatase inhibitors; Fulvestrant
Indications Advanced breast cancer; Brain metastases; HER2 negative breast cancer
Focus Adverse reactions; Therapeutic Use

Most Recent Events

16 Aug 2023 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2024.
29 Jul 2021 Status changed from not yet recruiting to recruiting.
18 Jun 2021 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com